Despite usual iron chelating therapy based on desferrioxamine, patients affected by β-thalassemia major (β-TM) often develop progressive heart failure caused by myocardial iron overload, which is the leading cause of mortality within the third decade of life. Heart transplantation is a limited therapeutic option, as very often these patients have multi-organ iron deposits and infective complications (particularly hepatitis C), secondary to frequent blood transfusions. We report the case of a 26-year-old male affected by β-TM with end-stage heart failure, who showed a dramatic improvement in symptoms and myocardial function when a new oral iron chelating agent, deferiprone, was added to standard therapy with desferrioxamine. © 2006 European Society of Cardiology.
Porcu, M., Landis, N., Salis, S., Corda, M., Orrù, P., Serra, E., … Galanello, R. (2007). Effects of combined deferiprone and desferrioxamine iron chelating therapy in β-thalassemia major end-stage heart failure. A case report. European Journal of Heart Failure, 9(3), 320–322. https://doi.org/10.1016/j.ejheart.2006.08.006